Table 3:
Demographics and Clinical/Laboratory Characterization of Study Subjects by Postvaccination Responses: SAD (Group C, inadequate post-pPA) versus Non-SAD (Group AB, adequate post-pPA).
| Group AB: Adequate Baseline-pPA (Non-SAD) | Group C: Adequate Post-pPA (SAD) | P value | |
|---|---|---|---|
| Patient cohort (%) | 251 (80) | 62 (20) | |
| Median age | 34 | 41 | .003 |
| Ethnicity (white /other) | 214/37 | 54/8 | .71 |
| Male/female | 88/163 | 23/39 | .76 |
| Recurrent infection (%) | 189 (75) | 52 (84) | .15 |
| No infection (%) | 62 (25) | 10 (16) | .2 |
| Chronic rhinosinusitis (%) | 106 (42) | 37 (60) | .014 |
| Recurrent acute sinusitis (%) | 50 (20) | 11 (18) | .70 |
| Recurrent upper respiratory infection (%) | 53(21) | 7 (11) | .08 |
| Allergy sensitization (%) | 94 (37) | 25 (40) | .68 |
| Asthma (%) | 106 (42) | 28 (45) | .68 |
| Allergic asthma (%) | 79 (31) | 21 (34) | .72 |
| Rhinitis (allergic and nonallergic) (%) | 196 (78) | 46 (74) | .51 |
| Allergic rhinitis (%) | 146 (58) | 31 (50) | .25 |
Abbreviations: pPA, percentage of protective (≥1.3 μg/mL) pneumococcal antibody serotypes/total tested serotypes; SAD: specific antibody deficiency.Note: Bold values indicate statistical significance.